Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Supernus PharmaceuticalsLTS:0LB2 -3.64%88 Debt-to-Equity is 0.04 as of Mar. 2026, which is 92% below its 10-year median of 0.52. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $41.29 (Modestly Overvalued). Among 813 Drug Manufacturers companies, Supernus Pharmaceuticals ranks better than 84.99% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Supernus Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
LTS:0LB2'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.52 Max: 0.9
Current: 0.04
During the past 13 years, the highest Debt-to-Equity Ratio of Supernus Pharmaceuticals was 0.90. The lowest was 0.01. And the median was 0.52.
LTS:0LB2's Debt-to-Equity is ranked better than 84.99% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs LTS:0LB2: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Supernus Pharmaceuticals Debt-to-Equity Related Terms
Supernus Pharmaceuticals Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0LB2 vs RGC, BCRX, PBH: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (LTS:0LB2) has a Debt-to-Equity of 0.04 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Supernus Pharmaceuticals and its competitors. This is 92% below median its historical median of 0.52. Over the past decade, Supernus Pharmaceuticals' Debt-to-Equity has ranged from 0.01 to 0.90. According to the industry distribution chart, Supernus Pharmaceuticals ranks #122 out of 813 companies in the Drug Manufacturers industry, placing it in the top 15%.
Is Supernus Pharmaceuticals' Debt-to-Equity too high?
Supernus Pharmaceuticals' current Debt-to-Equity of 0.04 is 92% below median its 10-year median of 0.52. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.90. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Supernus Pharmaceuticals' value of 0.04 is 85.2% below this industry median. Based on the distribution chart, Supernus Pharmaceuticals ranks #122 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Debt-to-Equity compare to RGC and BCRX?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #122 out of 813 companies for Debt-to-Equity. This places Supernus Pharmaceuticals in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.27. Supernus Pharmaceuticals' value of 0.04 is 85.2% below this benchmark. Historically, Supernus Pharmaceuticals' own Debt-to-Equity has ranged from 0.01 to 0.90 over the past decade. While the company's 10-year median is 0.52 vs. the industry median of 0.27, Supernus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supernus Pharmaceuticals's current Debt-to-Equity of 0.04 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Supernus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current Debt-to-Equity is 0.04, which is 92% below median its own 10-year median of 0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $41.29, compared to a current price of $46.73 — trading 13.2% above its estimated fair value. The current Debt-to-Equity is 0.04, which is 92% below median its 10-year median of 0.52 and 85.2% below the Drug Manufacturers industry median of 0.27. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Debt-to-Equity is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $46.73 is trading 13.2% above its estimated GF Value™ of $41.29.
GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LTS:0LB2:
Debt-to-Equity: 0.04 (92% below median its 10-year median of 0.52)
GF Value™: $41.29 vs. price of $46.73 (13.2% above fair value)
Industry Position: 85.2% below the Drug Manufacturers median (#122 of 813)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score
Get the complete analysis for LTS:0LB2
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
